Hoth Therapeutics, a clinical-stage biopharmaceutical company, has filed two U.S. provisional patent applications that significantly expand its intellectual property portfolio and establish a new oncology-focused dermatology platform targeting treatment-induced skin toxicity from modern cancer therapies. The filings secure priority intellectual property rights around the use of HT-001 to treat dermatologic toxicities across multiple oncology treatment modalities, including radiation therapy a...